个人简介：

王艺瑾，南方科技大学医学院副教授，博士生导师。2012 年和 2016 年分别于荷兰瓦赫宁根大学与研究中心、荷兰伊拉斯姆斯大学医学中心获得硕士和博士学位。美国伊利诺伊大学访问学者。王艺瑾在国际上较早开展戊型肝炎研究。其课题组以病毒性肝炎的转化研究为核心，通过多组学分析及筛选技术，揭示病毒-宿主相互作用、病毒激活及逃逸天然免疫机制、病毒特异性抵抗干扰素应答新机制，并基于此开发新型高效抗病毒药物。同时通过临床大队列研究，明确戊型肝炎慢性化、重症化、肝外感染的危险因素，以及在特殊人群中的预后判断。其研究方向还扩展到丙型肝炎病毒（HCV）、乙型肝炎病毒（HBV）以及非感染性肝病的发病机制研究。依托感染性疾病的研究，课题组同时开展以线粒体动态调控为主要研究对象的脓毒症多器官损伤研究。在非感染性肝病方面，课题组通过单细胞及空间转录组测序技术，揭示非酒精性脂肪肝空间免疫细胞特征，解释各种治疗手段中，患者不同预后的免疫学机制。

王艺瑾获得多个人才项目及国家级课题基金资助：入选广东省珠江人才计划，入选北京市科技新星计划，深圳市海外高层次人才B类。入选解放军总医院“3+1”创新人才建设工程新秀人才，入选解放军总医院优青培育计划；曾承担多项荷兰科技部项目及荷兰肝肠病协会课题基金，现主持国家自然科学基金 3 项， 参与国家科技重大专项等项目； 近年发表 SCI 论文 48 篇，其中以第一/通讯作者在Lancet Respiratory Medicine，Gastroenterology，Journal of Hepatology， Hepatology，EbioMedicine等知名权威期刊发表论文22篇，总影响因子450余分，他引9000余次，主编英文论著 1 本；相关成果多次被三大国际肝病年会选为口头报告并获青年学者奖。

教育背景：

2012/11–2016/09，荷兰伊拉斯姆斯大学医学中心，肝肠病学，博士

2010/09–2012/08，荷兰瓦赫宁根大学与研究中心，生物技术医学方向，硕士

2006/09–2010/07，南京医科大学，生物技术，学士

工作经历：

2020/11-至今，  南方科技大学医学院，副教授 

2016/09-2020/10， 解放军总医院第五医学中心，病理诊断与研究中心，副研究员

获奖情况及荣誉：

2021，中华医学科技奖，医学科学技术三等奖

2020,   亚太肝病学会 （APASL）授予的旅行奖

2019， 北京市科委授予的北京市科技新星

2019， 解放军总医院授予的创新人才建设工程新秀人才

2019， 欧洲肝病学会（EASL）授予的青年学者奖

2019， 中美肝病学院 优秀论文报告奖

2019， 北京医学会 北京肝病年会，优秀论文

2018,   欧洲肝病年会（EASL）授予的青年学者奖

2018， 亚太肝病年会（APASL）授予的青年学者奖

2018， 北京医学会 北京肝病年会，优秀论文

2017， 荷兰肝病学会（NVGE）授予的 Veldhovenbeurs 奖

2017， 中华医学会 脂肪性肝病联合学术会议,优秀论文

2017， 北京医学会 北京肝病学术年会，优秀论文

2014， 欧洲肝病年会（EASL）授予的青年学者奖

研究领域：

其课题组以病毒感染的转化研究为核心，重点研究戊型肝炎病毒（HEV）的感染机制及开展抗病毒药物研究。通过结合最先进的分子、细胞生物学技术及多组学分析，揭示病毒-宿主的相互作用，病毒激活及逃逸天然免疫机制，并基于此开发新型高效抗病毒药物。同时通过临床大队列研究，明确HEV感染慢性化、重症化、肝外感染的危险因素，以及在特殊人群中的预后判断。同时，依托感染性疾病的研究，发现和揭示天然免疫应答新机制，重点关注于核苷酸合成抑制及线粒体功能调控。此外，其研究领域还扩展到非感染性肝病（非酒精性脂肪性肝病、肝细胞癌、胆管细胞癌）的无创诊断标志物研究。

学术任职：

2018 年 7 月 - 至今，中国研究型医院学会分子诊断医学专业委员会临床分子检验学组副组长

2018 年 7 月 - 至今，北京医学会肝病学分会肝病学分会青年委员

发表论文：

1. Zhou H#, Dai Z#, Li J, Wang J, Zhu H, Chang X, Wang Y*. TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury. Metabolism. 2023; 140:155383. (Corresponding Author)

2. Zhu H#, Dai Z#, Liu X#, Zhou H, Wang Y*. Serine/threonine kinase 3 promotes oxidative stress and mitochondrial damage in septic cardiomyopathy through inducing Kelch-like ECH-associated protein 1 phosphorylation and nuclear factor erythroid 2-related factor 2 degradation. Int J Biol Sci. 2023 (Corresponding Author)

3. Li R#, Dai Z#, Liu X#, Wang C, Huang J, Xin T, Tong Y, Wang Y*. Interaction between dual specificity phosphatase-1 and cullin-1 attenuates alcohol-related liver disease by restoring p62-mediated mitophagy. Int J Biol Sci. 2023 (Corresponding Author)

4. Wang C, Wang Y*. The role and mechanism of action of mitophagy in various liver diseases. Antioxid Redox Signal. 2022. (Corresponding Author)

5. Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, et al. Wang Y*, Pan Q*. Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology. 2022; 75:196-212. (Co-Corresponding Author)

6. Xu Z#, Shi L#, Wang Y#, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420-2. (Co-First Author)

7. Wang Y#, Liu S#, Liu H#, Li W#, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of hepatology. 2020; 73:807-16.

8. Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.Gastroenterology. 2014; 146:1775-83.

9. Wang Y, Chen G, Pan Q, Zhao J. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. Gastroenterology. 2018; 154:1199-201.

10. Li P, Li Y, Wang Y*, Liu J, Lavrijsen M, Li Y, et al. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. Sci Adv. 2022; 8:eabj5908. (Co-corresponding Author)

11. Wang Y#, Rao H#, Chi X#, Li B#, Liu H, Wu L, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine. 2019; 46:227-35.

12. Wang Y#*, Wang S#, Wu J#, Jiang Y#, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine. 2018; 36:122-30.

13. Wang Y#*, Liu H#, Liu S#, Yang C, Jiang Y, Wang S, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. Liver Int. 2019; 39:2291-300.

14. Wang L, Wang Y*, Liu S, Zhai X, Zhou G, Lu F, et al. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol. 2019. (Co-Corresponding Author)

15. Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy. 2016; 60:2834-48.

16. Wang Y, Liu H, Jiang Y, Pan Q, Zhao J. Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. Open Forum Infect Dis. 2020; 7:ofaa107.

17. Wang Y, Metselaar HJ, Peppelenbosch MP, Pan Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Current Opinion in Infectious Diseases. 2014; 27:303-8.

18. Wu J, Zhang X, Liu H, Guo N, Pan Q, Wang Y*. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clinical Biochemistry. 2019; 63:24-31. (Corresponding Author)

19. Wang Y, Liu S, Pan Q, Zhao J. Chronic hepatitis E in an immunocompetent patient. Clin Res Hepatol Gastroenterol. 2019.

20. Gao Y#, Wang Y#, Liu H#, Liu Z, Zhao J. Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholic steatohepatitis. Dig Liver Dis. 2020; 52:637-43. (Co-First Author)

21. Wang J#, Huang A#, Wang Y#, Ji D, Liang Q, Zhao J, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: A randomised open-label trial. Alimentary Pharmacology & Therapeutics. 2022; Accepted. (Co-First Author)

22. Li S#, Jiang L#, Li X#, Lin F#, Wang Y#, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020; 5. (Co-First Author)

23. Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology. 2018; 67:2096-112.

24. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology. 2014; 61:746-54.

25. Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, et al. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral Research. 2017; 140:1-12.

26. Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Research. 2016; 133:41-9.

27. Zhou X, Xu L, Wang Y, Wang W, Sprengers D, Metselaar HJ, et al. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antiviral research. 2015; 124:11-9.

28. Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrobial agents and chemotherapy. 2017; 61.

29. Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrobial agents and chemotherapy. 2014; 58:267-73.

30. Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, et al. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells. 2020; 9.

31. Zhang H, Rao H, Wang Y, Wang J, Kong X, Ji Y, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection. Journal of gastroenterology and hepatology. 2019; 34:458-65.

32. Zhang S, Qu C, Wang Y, Wang W, Ma Z, Peppelenbosch MP, et al. Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene. 2018; 675:157-64.

33. Jiang L, Yang M, Li X, Wang Y, Zhou G, Zhao J. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk. The Journal of clinical endocrinology and metabolism. 2018; 103:3974-85.

34. Yang M, Jiang L, Wang Y, Li X, Zou Z, Han T, et al. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. J Gastrointestin Liver Dis. 2019; 28:289-96.

35. Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, Pan Q. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Reviews in medical virology. 2019:e2075.

36. Wang W, Yin Y, Xu L, Su J, Huang F, Wang Y, et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science signaling. 2017; 10.

37. Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, et al. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology. 2017; 65:1823-39.

38. Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2016; 30:3352-67.

39. Wang W, Xu L, Brandsma JH, Wang Y, Hakim MS, Zhou X, et al. Convergent Transcription of Interferon-stimulated Genes by TNF-alpha and IFN-alpha Augments Antiviral Activity against HCV and HEV. Scientific reports. 2016; 6:25482.

40. Qu C, Zhang S, Wang W, Li M, Wang Y, van der Heijde-Mulder M, et al. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2019; 33:1008-19.

41. Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of viral hepatitis. 2016; 23:294-304.

42. Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, et al. Hepatitis E Virus Infects Neurons and Brains. The Journal of infectious diseases. 2017; 215:1197-206.

43. Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. Antiviral research. 2015; 123:120-31.

44. Hemachandra LP, Patel H, Chandrasena RE, Choi J, Piyankarage SC, Wang S, et al. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites. Cancer prevention research. 2014; 7:505-15.